A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels.
about
Role of key TYMS polymorphisms on methotrexate therapeutic outcome in portuguese rheumatoid arthritis patientsA miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistanceThe association between two polymorphisms in the TS gene and risk of cancer: a systematic review and pooled analysisUGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapyPharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy.G>C SNP of thymidylate synthase with respect to colorectal cancer.Pathway based analysis of SNPs with relevance to 5-FU therapy: relation to intratumoral mRNA expression and survival.Evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidinesThymidylate synthase expression and prognosis in colorectal cancer: a meta-analysis of colorectal cancer survival data.Polymorphisms in thymidylate synthase gene and susceptibility to breast cancer in a Chinese population: a case-control analysis.Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker.Pancytopenia and Severe Gastrointestinal Toxicities Associated with 5-Fluorouracil in a Patient with Thymidylate Synthase (TYMS) PolymorphismLoss of heterozygosity at thymidylate synthase locus in Barrett's metaplasia, dysplasia, and carcinoma sequences.Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 yearsGenetic variation in microRNA networks: the implications for cancer research.Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients.Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?Genes and abdominal aortic aneurysm.MTHFR Glu429Ala and ERCC5 His46His polymorphisms are associated with prognosis in colorectal cancer patients: analysis of two independent cohorts from Newfoundland.MicroRNA-433 negatively regulates the expression of thymidylate synthase (TYMS) responsible for 5-fluorouracil sensitivity in HeLa cells.One-carbon metabolism pathway gene variants and risk of clear cell renal cell carcinoma in a Chinese population.Nutrients and genetic variation involved in one-carbon metabolism and Hodgkin lymphoma risk: a population-based case-control study.NAT1, NOS3, and TYMS genotypes and the risk of conotruncal cardiac defects.Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery.Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects.Genetic variants in 3'-UTRs of methylenetetrahydrofolate reductase (MTHFR) predict colorectal cancer susceptibility in Koreans.Genetic variant rs16430 6bp > 0bp at the microRNA-binding site in TYMS and risk of sporadic breast cancer risk in non-Hispanic white women aged ≤ 55 yearsAssociation between folate metabolism-related polymorphisms and colorectal cancer risk.Polymorphism in one-carbon metabolism pathway affects survival of gastric cancer patients: Large and comprehensive studyDelimiting Allelic Imbalance of TYMS by Allele-Specific AnalysisPharmacogenomics and stomach cancer.Pharmacogenetics of methotrexate.Predictive diagnostics in colorectal cancer: impact of genetic polymorphisms on individual outcomes and treatment with fluoropyrimidine-based chemotherapy.Genetic factors influencing pyrimidine-antagonist chemotherapy.Pharmacogenetics of folate-related drug targets in cancer treatment.Pharmacogenetics of colorectal cancer.The Effectiveness of Pemetrexed Monotherapy Depending on Polymorphisms in TS and MTHFR Genes as Well as Clinical Factors in Advanced NSCLC Patients.Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy.A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202.The role of pharmacogenetics in cancer therapeutics.
P2860
Q21131938-CD31FD0B-B2A2-412D-9CBD-A79A7638349CQ24679991-F34CDF93-1B5F-4628-B103-28281481BB35Q26866504-6A183A01-61D8-42B5-AB95-68C9705850A5Q27851574-BD428EC7-7EA4-456E-8C98-65EBC3244F71Q27863360-317E9E5B-EAD4-4D73-9044-61F985DE708CQ27863368-07AD5EBC-74F3-48AA-AD79-BA42CBBC4854Q27863385-79F1D273-4D10-4B00-BB55-42E33C519394Q28534572-52BB929F-1406-4020-83FC-A10D06A0751AQ30570866-2E827289-9E05-4033-B54C-84B5CB7465EEQ33244608-A726CBC8-41D5-4914-B3BC-0190BE3958BFQ33337970-B7EC63B1-C1CC-4EF7-8070-C552BE2567BFQ33436235-3469831F-48E8-49EE-875C-3E750F958D84Q33449893-71FD3E23-E28D-4682-B8AE-7C992BA36329Q34008793-94E7C641-D013-46C2-BEC8-694B696779D0Q34177121-17F81FA3-8975-4CA9-AE9E-1274B320F76CQ34491507-D2AEFA1B-2A41-45A0-9CFA-CD8BB0FE0C75Q34559803-24B6FF2A-32D2-4CF7-954C-6AB3B2896252Q34683905-EBCE1887-3E13-4230-96D5-379F106B92B9Q34692175-6782FC40-A57B-46E1-B79A-681B612A0026Q34894800-42E8C37C-AAF9-4394-B840-37167E5A0982Q35053902-6D7C1906-6250-445A-80F4-138013198B7BQ35465901-E4F5566C-B00C-4ABD-A204-B88BD2CEBC6DQ35500353-5C9C5F84-1699-48B4-9DF1-EC458DDDA59AQ35583987-37BA0D11-1ABC-462D-A895-0505794CF280Q35584647-0EDE6C30-62FE-4711-A167-808021537186Q35687058-D91FADD5-61AA-4414-A2B4-562D33673DA9Q35731144-86F30A3F-C9D9-4ED4-BF96-6458BC4CF61AQ35753712-0193B390-3F85-4365-9FD9-C6E6949B26ECQ35832445-7E071DD5-DD5C-4F71-8404-3F4109A49368Q35858190-98F9BDD4-C0F3-4B04-8CE8-8F1287A8C7B4Q35873676-F863119B-AA41-41D2-815D-E091A8BD8181Q35911142-76B33FC4-ECF4-4F80-8C11-E8422E354131Q36117701-CD078DC2-1146-43AA-9D71-0A8734F67566Q36205831-1C739E58-FBA6-4B6C-884D-560578F2327BQ36278007-90BBBC32-4AA7-4D3C-AB73-2E0022AB1AA2Q36326214-3E8A2EC3-41B0-47C5-8E89-09C0F4DB382AQ36378565-535522EE-EC48-491B-BFE2-05658181C977Q36441493-F6C42EC6-7757-424C-AC3C-8E64669F8314Q36459140-C1C9CC19-4BF3-42E5-A04E-EA0A77980908Q36536674-FD7615C4-F535-4710-BEA8-0C4894A15F4E
P2860
A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
A 6 bp polymorphism in the thy ...... d intratumoral TS mRNA levels.
@en
type
label
A 6 bp polymorphism in the thy ...... d intratumoral TS mRNA levels.
@en
prefLabel
A 6 bp polymorphism in the thy ...... d intratumoral TS mRNA levels.
@en
P2093
P1476
A 6 bp polymorphism in the thy ...... d intratumoral TS mRNA levels.
@en
P2093
Jan Stoehlmacher
Michael V Mandola
Robert D Ladner
Susan Groshen
Syma Iqbal
P304
P356
10.1097/00008571-200405000-00007
P577
2004-05-01T00:00:00Z